Association of pregnancy with engagement in HIV care among women with HIV in the UK: a cohort study.


Journal

The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355

Informations de publication

Date de publication:
12 2021
Historique:
received: 27 04 2021
revised: 12 08 2021
accepted: 18 08 2021
pubmed: 12 11 2021
medline: 15 3 2022
entrez: 11 11 2021
Statut: ppublish

Résumé

Women with HIV face challenges in engaging in HIV care post partum. We aimed to examine changes in engagement in HIV care through clinic attendance before, during, and after pregnancy, compared with matched women with HIV who had never had a recorded pregnancy. In this cohort study, we describe changes in engagement in HIV care before, during, and after pregnancy among women with HIV from the UK Collaborative HIV Cohort (CHIC) study from 25 HIV clinics in the UK with a livebirth reported to the National Surveillance of HIV in Pregnancy and Childhood between Jan 1, 2000, and Dec 31, 2017. To investigate whether changes were specific to HIV, we compared these changes to those over equivalent periods among non-pregnant women with HIV in the UK CHIC study matched for ethnicity, year of conception, age, CD4 cell count, viral suppression, and antiretroviral therapy use. Analyses were via logistic regression using generalised estimated equations with an interaction between case-control status (pregnant women vs non-pregnant women) and pregnancy or pseudo pregnancy (for non-pregnant women) stage. 1116 matched pairs of pregnant and non-pregnant women were included (median age 34 years [IQR 30-38], 80·1% Black African, 12·5% white). 69 330 person-months of follow-up were recorded, 25 412 in the before stage, 18 897 during, and 25 021 after pregnancy or pseudo pregnancy stages. Among pregnant women, the proportion of time engaged in care increased during pregnancy (8477 [90·5%] of 9371 person-months) and after pregnancy (10 501 [84·6%] of 12 407), compared with before pregnancy (9979 [78·5%] of 12 707). Among non-pregnant women in the control group, engagement in HIV care remained stable across the three equivalent stages (9688 [76·3%] of 12 705 person-months before pseudo pregnancy; 7463 [78·3%] of 9526 during pseudo pregnancy; and 9892 [78·4%] of 12 614 after pseudo pregnancy). The association of engagement in HIV care with pregnancy or pseudo pregnancy stage differed significantly by case-control status (p Women with HIV and a pregnancy resulting in a livebirth were more likely to engage in HIV care post partum when compared with before pregnancy. A detailed understanding of the reason for this finding could support interventions to maximise engagement in HIV care for all women with HIV. Medical Research Council and National Institute for Health Research.

Sections du résumé

BACKGROUND
Women with HIV face challenges in engaging in HIV care post partum. We aimed to examine changes in engagement in HIV care through clinic attendance before, during, and after pregnancy, compared with matched women with HIV who had never had a recorded pregnancy.
METHODS
In this cohort study, we describe changes in engagement in HIV care before, during, and after pregnancy among women with HIV from the UK Collaborative HIV Cohort (CHIC) study from 25 HIV clinics in the UK with a livebirth reported to the National Surveillance of HIV in Pregnancy and Childhood between Jan 1, 2000, and Dec 31, 2017. To investigate whether changes were specific to HIV, we compared these changes to those over equivalent periods among non-pregnant women with HIV in the UK CHIC study matched for ethnicity, year of conception, age, CD4 cell count, viral suppression, and antiretroviral therapy use. Analyses were via logistic regression using generalised estimated equations with an interaction between case-control status (pregnant women vs non-pregnant women) and pregnancy or pseudo pregnancy (for non-pregnant women) stage.
FINDINGS
1116 matched pairs of pregnant and non-pregnant women were included (median age 34 years [IQR 30-38], 80·1% Black African, 12·5% white). 69 330 person-months of follow-up were recorded, 25 412 in the before stage, 18 897 during, and 25 021 after pregnancy or pseudo pregnancy stages. Among pregnant women, the proportion of time engaged in care increased during pregnancy (8477 [90·5%] of 9371 person-months) and after pregnancy (10 501 [84·6%] of 12 407), compared with before pregnancy (9979 [78·5%] of 12 707). Among non-pregnant women in the control group, engagement in HIV care remained stable across the three equivalent stages (9688 [76·3%] of 12 705 person-months before pseudo pregnancy; 7463 [78·3%] of 9526 during pseudo pregnancy; and 9892 [78·4%] of 12 614 after pseudo pregnancy). The association of engagement in HIV care with pregnancy or pseudo pregnancy stage differed significantly by case-control status (p
INTERPRETATION
Women with HIV and a pregnancy resulting in a livebirth were more likely to engage in HIV care post partum when compared with before pregnancy. A detailed understanding of the reason for this finding could support interventions to maximise engagement in HIV care for all women with HIV.
FUNDING
Medical Research Council and National Institute for Health Research.

Identifiants

pubmed: 34762836
pii: S2352-3018(21)00194-6
doi: 10.1016/S2352-3018(21)00194-6
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e747-e754

Subventions

Organisme : Medical Research Council
ID : MR/M004236/1
Pays : United Kingdom

Investigateurs

Jonathan Ainsworth (J)
Sris Allan (S)
Jane Anderson (J)
Ade Apoola (A)
David Chadwick (D)
Duncan Churchill (D)
Valerie Delpech (V)
David Dunn (D)
Ian Fairley (I)
Ashini Fox (A)
Richard Gilson (R)
Mark Gompels (M)
Phillip Hay (P)
Rajesh Hembrom (R)
Teresa Hill (T)
Margaret Johnson (M)
Sophie Jose (S)
Stephen Kegg (S)
Clifford Leen (C)
Dushyant Mital (D)
Mark Nelson (M)
Hajra Okhai (H)
Chloe Orkin (C)
Adrian Palfreeman (A)
Andrew Phillips (A)
Deenan Pillay (D)
Ashley Price (A)
Frank Post (F)
Jillian Pritchard (J)
Caroline Sabin (C)
Achim Schwenk (A)
Anjum Tariq (A)
Roy Trevelion (R)
Andy Ustianowski (A)
John Walsh (J)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests ST has received funding from Gilead Sciences for the development and presentation of educational material from Gilead Sciences, and Sophia Forum for consulting on the development of a programme of support for women with HIV. FB has received funding for development and presentation of educational material from Gilead Sciences. CT has received funding from ViiV Healthcare for participation in advisory boards and Penta Foundation for projects. CAS has received funding for membership of data safety and monitoring boards, advisory boards, and for preparation of educational materials from Gilead Sciences, ViiV Healthcare, and Janssen-Cilag. All other authors declare no competing interests.

Auteurs

Hajra Okhai (H)

Institute for Global Health, University College London, London, UK; National Institute for Health Research Health Protection Research Unit in Blood-borne and Sexually Transmitted Infections, University College London, London, UK. Electronic address: h.okhai@ucl.ac.uk.

Shema Tariq (S)

Institute for Global Health, University College London, London, UK.

Fiona Burns (F)

Institute for Global Health, University College London, London, UK.

Yvonne Gilleece (Y)

Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; Brighton and Sussex Medical School, Brighton, UK.

Rageshri Dhairyawan (R)

Department of Infection and Immunity, Barts Health NHS Trust, London, UK.

Teresa Hill (T)

Institute for Global Health, University College London, London, UK.

Helen Peters (H)

Institute for Global Health, University College London, London, UK; Integrated Screening Outcomes Surveillance Service, Great Ormond Street Institute of Child Health, University College London, London, UK.

Claire Thorne (C)

Institute for Global Health, University College London, London, UK; Integrated Screening Outcomes Surveillance Service, Great Ormond Street Institute of Child Health, University College London, London, UK.

Caroline A Sabin (CA)

Institute for Global Health, University College London, London, UK; National Institute for Health Research Health Protection Research Unit in Blood-borne and Sexually Transmitted Infections, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH